CD4 and multiple sclerosis: In general, the anti-rheumatic effects of such FDA-approved drugs, together with their wide usage against multiple sclerosis and rheumatoid arthritis, respectively, highlights the interesting possibility of repositioning immune-modulating drugs targeting the pathogenic CD4+ T cell response for these virus-induced joint and muscular pathologies.